UnitedHealth Group 8-K
PositiveEarningsGuidance raised
Medical cost management, pricing and benefit changes lifted UnitedHealthcare and Optum earnings; FY2026 outlook raised.
Filed 2026-10-13 06:14 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q3 2026 results and raised FY2026 earnings outlook. Revenue edged down Y/Y, while operating earnings and EPS increased; management cited medical cost management, pricing and benefit changes, and execution across UnitedHealthcare and Optum. The company also outlined healthcare affordability and access initiatives, with further commitments expected in 2027.
Key Figures
| Metric | Q3 2026 | 9M 2026 |
|---|---|---|
| Revenue | $112.7B, -0.4% Y/Y | $336.4B, +0.6% Y/Y |
| Earnings from operations | $6.56B, +52.1% Y/Y | $23.5B, +26.7% Y/Y |
| Net earnings attributable to UnitedHealth Group common shareholders | $4.11B, +75.0% Y/Y | $15.9B, +31.8% Y/Y |
| Diluted EPS (GAAP) | $4.56, +76.1% Y/Y | $17.50, +32.5% Y/Y |
| Adjusted diluted EPS (non-GAAP) | $4.69, +60.6% Y/Y | $18.30, +28.7% Y/Y |
| Cash flows from operations | $5.1B | $25.1B, +35.0% Y/Y |
- Medical care ratio was 88.4% vs 89.9% Y/Y, including $610M of net favorable prior-period reserve development related to 2026 dates of service. The operating cost ratio declined to 12.8% from 13.5%, reflecting efficiencies partly offset by investment in technology, processes and people.
- UnitedHealthcare revenue was $86.3B vs $87.1B Y/Y and earnings from operations were $2.83B vs $1.81B. Optum revenue was $66.9B vs $69.2B and earnings from operations were $3.73B vs $2.51B; Optum Health revenue fell 10% as it served fewer value-based care patients in markets without sufficient presence to sustain clinicians.
- Debt-to-capital was 41.7% at quarter-end vs 41.2% at Q2-end; the company targets ≈40.0% by year-end. Nine-month share repurchases were $5.03B vs $5.55B, with diluted weighted-average shares of 906M vs 912M; dividends paid were $6.17B vs $5.91B.
Guidance
FY2026 outlook raised overall; metric-specific prior outlook figures were not stated.
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Diluted EPS (GAAP) | FY2026 | At least $19.50 | — | — |
| Adjusted diluted EPS (non-GAAP) | FY2026 | At least $20.50 | — | — |
Investor Takeaways
- Watch progress against the company’s end-2026 prior-approval reduction commitments, including eliminating 30% of current volume.
- Track the 2027 Medicare Advantage Stars outcome: the company reported at least 69% of members in plans rated 4+ stars.
The summary is written by an AI model reading the filing.
Model 005 · prompt 8bef31e277